Rivaroxaban versus warfarin for the management of left ventricle thrombus

• Main Authors: Monirah A. Albabtain, Yahya Alhebaishi, Ola Al-Yafi, Hatim Kheirallah, Adel Othman, Haneen Alghosoon, Amr A. Arafat, Ahmed Alfagih
• Format: Article
• Language: English
• Published: SpringerOpen 2021-05-01
• Series: The Egyptian Heart Journal
• Subjects: Left ventricle thrombus; Non-vitamin K dependent oral anticoagulant rivaroxaban; Warfarin
• Online Access: https://doi.org/10.1186/s43044-021-00164-7

Abstract Background Rivaroxaban has been recently introduced for the management of non-valvular intra-cardiac thrombosis with variable results. We aimed to compare the results of the off-label use of rivaroxaban versus warfarin in the management of patients with left ventricle (LV) thrombus. This research is a retrospective study conducted on 63 patients who had LV thrombus from January to December 2016. We compared patients treated with warfarin (n=35) to patients who had rivaroxaban (n=28), and study outcomes were time to thrombus resolution, bleeding, stroke, and mortality. Results The median duration of treatment was 9.5 (25th-75th percentiles: 6-32.5) months for rivaroxaban and 14 (3-41) months for warfarin. Thrombus resolution occurred in 24 patients in the warfarin group (68.6%) and 20 patients in the rivaroxaban group (71.4%). The median time to resolution in the warfarin group was 9 (4-20) months and 3 (2-11.5) months in the rivaroxaban group. Thrombus resolution was significantly faster in patients on rivaroxaban (p= 0.019). Predictors of thrombus resolution were thrombus surface area (HR: 1.21; CI 95% (1.0-1.46); p= .048) and the use of rivaroxaban (HR: 1.92; CI 95% (1.01-3.65); p= 0.048). There was no difference in stroke, bleeding, and mortality between both groups. Conclusion Rivaroxaban was as effective and safe as warfarin in managing patients with left ventricle thrombus. Larger randomized clinical trials are recommended to confirm our findings.